Glucoma and intraocular pressure in EPIC-Norfolk Eye Study: cross sectional study

Michelle P Y Chan,1 David C Broadway,3 Anthony P Khawaja,4 Jennifer L Y Yip,4 David F Garway-Heath,5,6 Jennifer M Burr,7 Robert Luben,4 Shabina Hayat,4 Nichola Dalzell,4 Kay-Tee Khaw,4 Paul J Foster,5,6

ABSTRACT
OBJECTIVES
To report the distribution of intraocular pressure (IOP) by age and sex and the prevalence of glaucoma.

DESIGN
Community based cross sectional observational study.

SETTING
EPIC-Norfolk cohort in Norwich and the surrounding rural and urban areas.

PARTICIPANTS
8623 participants aged 48-92 recruited from the community who underwent ocular examination to identify glaucoma.

MAIN OUTCOME MEASURES
Prevalence and characteristics of glaucoma, distribution of IOP, and the sensitivity and specificity of IOP for case finding for glaucoma.

RESULTS
The mean IOP in 8401 participants was 16.3 mm Hg (95% confidence interval 16.2 mm Hg to 16.3 mm Hg; SD 3.6 mm Hg). In 363 participants (4%), glaucoma was present in either eye; 314 (87%) had primary open angle glaucoma. In the remaining participants, glaucoma was suspected in 607 (7%), and 863 (10.0%) had ocular hypertension. Two thirds (242) of those with glaucoma had previously already received the diagnosis. In 76% of patients with newly diagnosed primary open angle glaucoma (83/107), the mean IOP was under the threshold for ocular hypertension (21 mm Hg). No one IOP threshold provided adequately high sensitivity and specificity for diagnosis of glaucoma.

CONCLUSIONS
In this British community, cases of glaucoma, suspected glaucoma, and ocular hypertension represent a large number of potential referrals to the hospital eye service. The use of IOP for detection of those with glaucoma is inaccurate and probably not viable.

Introduction
Glaucoma is the leading cause of irreversible blindness in the world1 and the second most common cause of registered blindness in England and Wales.2 It comprises a group of ocular diseases of progressive damage to the optic nerve, with characteristic structural changes to the optic disc and visual field defects.3 Glaucoma and suspected glaucoma combined account for the sixth largest share of National Health Service (NHS) outpatient attendances in England, after general medical examination, breast cancer, schizophrenia, prostate cancer, and joint pain.4 The most common type of glaucoma among white people is primary open angle glaucoma (POAG); primary angle closure glaucoma (PACG), which results from occlusion of aqueous humour outflow, is more common among Asian people.5 Secondary glaucoma results from a diverse range of ocular and systemic conditions. Raised intraocular pressure (IOP) is the major modifiable risk factor for primary open angle glaucoma,6,8 but around half of people with glaucoma present with IOP below 21 mm Hg, which is the threshold for ocular hypertension (raised IOP without any evidence of glaucoma).9 The EPIC-Norfolk Eye Study, initiated in 2004, is the most recent large scale eye survey in the UK. We examined the prevalence and characteristics of glaucoma and distribution of IOP in the study participants.

Methods
The European Prospective Investigation of Cancer (EPIC) study is a pan-European multi-cohort study designed to investigate the lifestyle determinants of risk of cancer. The EPIC-Norfolk cohort was established in the city of Norwich and the surrounding rural and urban areas, in the eastern English county of Norfolk, in 1993-97.10 A total of 30 645 men and women aged 40-79 were recruited at a baseline survey from the databases of 35 general practices. The predominant ethnicity of the cohort was white, and it included individuals across the range of socioeconomic status and educational achievements. The EPIC-Norfolk Eye study was carried out in 2004-11, when ophthalmic data were collected from 8623 participants.11

WHAT IS ALREADY KNOWN ON THIS TOPIC
Glaucoma is the leading cause of irreversible blindness in the world and the second most common cause of registered blindness in England and Wales. The management of glaucoma, suspected glaucoma, and ocular hypertension accounts for a considerable amount of NHS outpatient resources. While the prevalence of glaucoma has been reported in many population studies worldwide, there are no recent data for the UK.

WHAT THIS STUDY ADDS
This study provides the most current data on prevalence and type of glaucoma in a British community and identified a large number of people with ocular hypertension and suspected glaucoma. The large number of people with confirmed glaucoma and intraocular pressure under the threshold for ocular hypertension (21 mm Hg) reinforces the weakness of reliance on this for detection of glaucoma.
The first 443 sequential participants had IOP measured with a non-contact tonometer (AT555, Reichert Corporation, Philadelphia, PA, USA). In the remaining participants IOP was measured three times in each eye with the ocular response analyser (ORA) non-contact analyser (Reichert Corporation, Philadelphia, PA, USA) with software version 3.01. This flattens the cornea with a jet of air and uses an electro-optical system to measure the air pressures at which the cornea flattens both inwards and outwards. The average of the two pressure values are calibrated linearly against the Goldmann applanation tonometer (GAT) to provide a Goldmann-equivalent IOP measurement (IOPg, mm Hg). A systematic review showed that among 12 studies that directly compared the agreement between IOPg and GAT, the mean difference between the two (IOPg-GAT) is 1.5 mm Hg (95% predicted interval −0.6 mm Hg to 3.7 mm Hg). The glaucoma status of the participants was determined from a systematic examination that included visual acuity, tonometry, and assessment of the optic nerve head (Heidelberg Retina Tomograph II) and the peripapillary nerve fibre layer with scanning laser polarimetry (GDx VCC, Zeiss, Dublin, CA, USA). A 24-2 central threshold visual field test (Humphrey 750i Visual Field Analyzer, Carl Zeiss Meditech, Welwyn Garden City, UK) was performed in those participants with abnormal findings on HRT or GDx VCC and in one in 10 with normal findings. Those with abnormal findings who met a set of predefined criteria designed to detect glaucoma were referred to the eye department of the Norfolk and Norwich University Hospital for a definitive eye examination by a consultant ophthalmologist with a specialist interest in glaucoma (DCB). A detailed description of the study design has been published previously. Glaucoma was defined as the presence of characteristic structural abnormalities of the optic disc and visual field loss, with no other explanations for the disc and field appearances. The differentiation between high tension and normal tension glaucoma was based on IOP level before glaucoma treatment started. Suspected glaucoma was defined as the presence of early or minor glaucomatous disc features, associated with a normal visual field or the absence of visual field data. Ocular hypertension was defined as IOP >21 mm Hg with no features of glaucoma in the optic disc or visual field. Specific quantitative methods and principles for diagnosis of primary open angle glaucoma and suspected primary open angle glaucoma followed the diagnostic principles from the International Society of Geographical and Epidemiological Ophthalmology (ISGEO). To limit false positive or false negative results, another consultant glaucoma ophthalmologist (PJF) reviewed all examination findings and history in a subset of high risk participants. Figure 1 shows the flow of participants through the study and the diagnostic process. We determined glaucoma diagnosis per person by taking the clinically more serious diagnosis of either eye in the following hierarchy (most serious to least serious): glaucoma, suspected glaucoma, ocular hypertension (IOP >21 mm Hg), narrow angle spectrum (primary angle closure, primary angle closure suspect and narrow angles), and normal.

### Statistical analysis

The IOP reported for the cohort was the mean of the right and left eyes, with the ORA IOPg or the AT555 NCT values. We calculated sensitivities and specificities of IOP for glaucoma detection from the ability of various IOP thresholds to discriminate between participants with all cause glaucoma in either eye and those with no glaucoma in either eye. The reporting of this study conformed to the STROBE statement. All statistical analyses were performed with STATA (Stata/SE 13.1, StataCorp, College Station, TX).

### Results

There were 8623 participants in the EPIC-Norfolk Eye Study, with a mean age of 68.7 (range 48-92), and over half (55%) were women. Compared with the population estimates for Norfolk and for the UK, the study population was older and had a decreasing proportion of women with age, which is opposite to the Norfolk population was older and had a decreasing proportion of women with age, which is opposite to the Norfolk population. The reporting of this study conformed to the STROBE statement. All statistical analyses were performed with STATA (Stata/SE 13.1, StataCorp, College Station, TX).

---

**Fig 1 | Flow of participants through EPIC-Norfolk study**
and UK population’s trend of an increasing proportion of women with age (fig 2). Nearly all participants were white (99.4%), compared with 96.5% and 87.2%, respectively, in Norfolk and the UK.15

Tables 1 and 2 show the glaucoma diagnosis by eye and by person. A total of 363 participants (4.2%, 95% confidence interval 3.8% to 4.6%) had glaucoma in either eye, 314 had primary open angle glaucoma (3.6%, 3.3% to 4.0%), 607 (7.0%) had glaucoma in either eye, and 314 had primary open angle glaucoma were previously known. The prevalence of glaucoma in the study population increased with age and was higher in men than in women (table 4).

Fig 2 | Age and sex distribution of EPIC-Norfolk 3HC cohort compared with population of Norfolk and UK (2014 mid-year population estimates)

Table 1 | Diagnosis of glaucoma by eye in 8623 men and women aged 48-92 in EPIC-Norfolk cohort. Figures are numbers (percentage of participants)

| Diagnosis* | Right eye | Left eye |
|------------|-----------|----------|
| Normal     | 7091 (82.2) | 7061 (81.9) |
| Primary open angle glaucoma | 236 (2.7) | 230 (2.7) |
| High tension glaucoma | 121 (1.4) | 121 (1.4) |
| Normal tension glaucoma | 115 (1.3) | 109 (1.3) |
| Primary angle closure glaucoma | 20 (0.2) | 17 (0.2) |
| Secondary glaucoma | 9 (0.1) | 11 (0.1) |
| Subtotal with glaucoma | 265 (3.1) | 258 (3.0) |
| Suspected open angle glaucoma | 444 (5.2) | 443 (5.1) |
| Ocular hypertension and suspected open angle glaucoma | 67 (0.8) | 67 (0.8) |
| Suspected angle closure glaucoma | 27 (0.3) | 28 (0.3) |
| Secondary ocular hypertension /suspected open angle glaucoma | 2 (0.0) | 4 (0.1) |
| Subtotal suspected glaucoma | 540 (6.3) | 542 (6.3) |
| Ocular hypertension | 641 (7.4) | 670 (7.8) |
| Primary angle closure | 27 (0.3) | 32 (0.4) |
| Narrow angles | 36 (0.4) | 34 (0.4) |
| Not recorded | 23 (0.3) | 26 (0.3) |
| Total | 8623 (100) | 8623 (100) |

Table 2 | Diagnosis of glaucoma in 8623 men and women aged 48-92 in EPIC-Norfolk cohort. Figures are numbers (percentage of participants)

| Diagnosis* | No (%) of participants |
|------------|-------------------------|
| Normal     | 6713 (77.9) |
| Glaucoma   | 363 (4.2) |
| Suspected glaucoma | 607 (7.0) |
| Ocular hypertension | 863 (10.0) |
| Narrow angle spectrum | 54 (0.6) |
| Unrecorded | 23 (0.3) |
| Total      | 8623 (100) |

*More serious diagnosis of either eye used, from (most serious to least serious): glaucoma, suspected glaucoma, ocular hypertension, narrow angle spectrum (primary angle closure, primary angle closure suspect), normal, diagnosis not recorded.

Table 3 | Type of glaucoma in 363 men and women aged 48-92 with glaucoma in EPIC-Norfolk cohort. Figures are numbers (percentage of participants)

| Diagnosis* | No (%) of participants |
|------------|-------------------------|
| Primary open angle glaucoma | 314 (86.5) |
| High tension glaucoma | 157 (43.3) |
| Normal tension glaucoma | 157 (43.3) |
| Primary angle closure glaucoma | 29 (8.0) |
| Secondary glaucoma | 20 (5.5) |
| Total (all glaucoma) | 363 (100) |

Table 4 | Glaucoma by age and sex in 363 men and women aged 48-92 with glaucoma in EPIC-Norfolk cohort. Figures are numbers (percentage of age group)

| Age (years) | Men | Women |
|-------------|-----|-------|
| <55         | 1 (0.8) | 1 (0.5) |
| 55-60       | 1 (0.5) | 1 (0.5) |
| 60-65       | 19 (11.5) | 16 (9.5) |
| 65-70       | 4 (2.2) | 3 (1.7) |
| 70-75       | 5 (3.0) | 4 (2.4) |
| 75-80       | 3 (1.7) | 2 (1.2) |
| ≥80         | 1 (0.6) | 1 (0.6) |

*All cause glaucoma and primary open angle glaucoma.
IOP was measured in 8401 participants (7958 with ORA, 443 with AT555 NCT), 243 of whom used ocular hypotensive eye drops in either eye. Figure 3 shows the distribution of mean IOP of both eyes, which followed an approximately Gaussian distribution, with a right skew and an exaggerated peak. The cohort mean IOP was 16.3 mm Hg (95% confidence interval 16.2 mm Hg to 16.3 mm Hg; SD 3.6 mm Hg). Table 5 shows the distribution of IOP by age and sex. The mean IOP for glaucomatous eyes was 16.7 mm Hg (17.1 mm Hg to 18.1 mm Hg; range 4.0-45.6 mm Hg), and the percentage of eyes with glaucoma increased with IOP (fig 4). Of the 107 patients with a new diagnosis of primary open angle glaucoma, 76% (81) had mean IOP below 21 mm Hg.

Table 6 and figure 5 show the sensitivity and specificity of glaucoma detection at different IOP thresholds. Overall, sensitivity was poor at all levels shown, regardless of the additional refining parameters of age and sex, and there was no one single level that afforded both high sensitivity and specificity.

**Discussion**

In this large population based study, we found that intraocular pressure was not a sensitive or specific indicator of glaucoma. This is the most current large scale population study reporting glaucoma epidemiology in the UK. We found many participants with suspected glaucoma or ocular hypertension, confirming a large potential referral burden to the NHS. IOP has also been shown to be a poor case finding test for glaucoma.

**Principal findings and comparison with other studies**

Data on prevalence of glaucoma have been reported from populations in the US, Australia, Europe, and South East Asia. Recent data from the UK, however, is lacking, with the last published cross sectional population surveys being one from rural west of Ireland in 1993 and another from north London in 1998.

There were differences between the participants from EPIC-Norfolk and the local population of Norfolk as the study participants were not sampled systematically but recruited by inviting all adults aged >40 from GP practices. Apart from differences in age and sex composition, EPIC-Norfolk participants were less likely to live in deprived areas and were potentially healthier because of the volunteer nature of the study. The people with glaucoma identified in the cohort might therefore not be fully representative of the local or national population and are probably an underestimation of the true numbers. Nevertheless, results in this study corroborated many established trends in glaucoma epidemiology. The predominant type in our cohort was primary open angle glaucoma, a consistent finding among European populations. The prevalence increased with age, which is its strongest known risk factor. The prevalence of all cause glaucoma in those aged 48-92 was 4.2% (95% confidence interval 3.8% to 4.6%) and 3.7% (3.3% to 4.0%) for primary open angle glaucoma. This echoed findings from a meta-analysis in 2014, in which the prevalence of glaucoma (primary open angle glaucoma and primary angle closure glaucoma) for Europeans...
Table 6 | Sensitivity and specificity for detection of all cause glaucoma at different thresholds of intraocular pressure (IOP)

| Intraocular pressure threshold (mm Hg) | Sensitivity (%) | Specificity (%) |
|--------------------------------------|-----------------|-----------------|
|                                      | Overall | <65 | ≤65 | >65 | ≤70 | >70 | Men | Women | Overall | <65 | ≤65 | >65 | ≤70 | >70 | Men | Women |
| >19                                  | 45.0    | 36.7| 46.3| 45.6| 44.7| 49.2| 39.7| 73.2| 74.1| 72.6| 72.8| 73.6| 73.7| 72.7 |
| >20                                  | 36.3    | 26.5| 37.9| 34.0| 37.3| 42.4| 28.9| 81.0| 82.0| 80.3| 80.9| 81.0| 80.5| 81.3 |
| >21                                  | 30.0    | 24.5| 30.9| 28.2| 30.7| 35.1| 23.7| 86.9| 87.7| 86.4| 86.8| 87.0| 85.8| 87.7 |
| >22                                  | 25.4    | 22.5| 25.8| 23.3| 26.2| 30.4| 19.2| 91.2| 91.9| 90.7| 91.1| 91.3| 90.3| 91.9 |
| >23                                  | 20.5    | 18.4| 20.8| 20.4| 20.5| 24.6| 15.4| 94.0| 94.5| 93.8| 93.8| 94.5| 93.2| 94.7 |
| >24                                  | 16.7    | 14.8| 16.4| 16.5| 16.8| 20.9| 11.5| 96.0| 96.2| 95.9| 95.7| 96.4| 95.4| 96.5 |
| >25                                  | 12.1    | 12.2| 12.1| 10.7| 12.7| 16.2| 7.1 | 97.1| 97.0| 97.2| 96.9| 97.5| 96.6| 97.6 |
| >26                                  | 7.8     | 8.2 | 7.7 | 6.8 | 8.2 | 11.0| 3.9 | 98.0| 97.8| 98.1| 97.8| 98.3| 97.5| 98.4 |

In conclusion, this study confirms the high prevalence of glaucoma and suspected glaucoma in the UK.

A striking finding in the study was the large number of people with suspected glaucoma (7%) and ocular hypertension (10%). Collectively they represent a large number of potential referrals to the hospital eye services, many of whom remain under observation for up to five years. This is reflected by the existing burden in hospital eye services, whereby ocular hypertension accounts for 30-45% of the referrals it receives. Coupled with the fact that glaucoma is a chronic disease that needs regular and long term follow-up, it is no wonder that glaucoma and suspected glaucoma account for the sixth largest share of NHS outpatient attendances.

While raised IOP is the strongest risk factor after age for primary open angle glaucoma, our data reiterate that no single IOP level provides sufficiently high sensitivity and specificity for detection of glaucoma, as shown in figure 3, mirroring results from the Baltimore Eye Survey. This reinforces the principle that IOP alone without optic disc examination or a visual field test is not an effective screening tool for glaucoma.

Limitations of study
There were several sources of under-reporting of a diagnosis of glaucoma in this study. Only 18% of participants underwent visual field testing. A meta-analysis showed that lack of routine field testing in a population study was a study design factor that led to underdiagnosis. In our study, however, both disc and field abnormalities were prerequisites of diagnosis, supporting well established diagnostic principles used in most population cross sectional studies.

We used a multimodal optic disc examination to uncover glaucomatous damage and determine who was referred for a definitive exam. We therefore expect that few cases of glaucoma would have been missed. The number of cases of narrow angle spectrum is also likely to be underestimated, as gonioscopy or anterior chamber depth assessment on slit lamp were not part of the screening test, although those with primary open angle glaucoma should not have been missed because of that as all glaucoma suspects underwent a full examination.

Conclusion
In conclusion, this study confirms the high prevalence of glaucoma and suspected glaucoma in the UK.
We have reported the IOP distribution among the population and among those with glaucoma, confirming its poor case finding performance. These findings will be useful in the planning of ophthalmic services in the UK and help to revaluate the use of IOP in making referrals from the community to the hospital eye services.

We thank Haoqiang Zhu for his help in extracting visual field data, Pak Sang Lee for his technical assistance with the EPIC-Norfolk Eye Study, and Ananth Viswanathan FRCOphth for providing one of the visual field analysers used in this study.

**Contributors:** MPYC analysed and interpreted the data and drafted the manuscript. PJF and DCB contributed to the conception and design of the study and to data collection. APK and JLY contributed to data collection and interpretation. DGH contributed to the conception and design of the study and to data interpretation. JMB contributed to the conception of the study and to data management. KT contributed to the design of the study. ND contributed to the design of the study and to data acquisition. KTK contributed to the conception and design of the study and to data interpretation. All authors read and critically revised the manuscript and approved the final manuscript. MPYC and PJF are guarantors.

**Funding:** EPIC-Norfolk infrastructure and core functions are supported by grants from the Medical Research Council (G0401527) and Cancer Research UK (C6364/A2575). The clinic for the third health examination was funded by Research into Ageing (262). MPYC was supported by a joint Medical Research Council/Royal College of Ophthalmologists clinical training fellowship (G1001939/1) and the International Glaucoma Association. APK was a Welcome Trust clinical research fellow (0947912/10/Z). DGH, PJF, and IB were supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and University College London Institute of Ophthalmology, and PF received additional support from The Richard Desmond Charitable Trust. The views expressed in the publication are those of the authors and not necessarily those of the Department of Health.

**Competing interests:** All authors have completed the ICMJE uniform disclosure form at www.icmje.org/doi Disclosure.pdf and report: DFJ has received personal fees from Aerie, Alimera, Allergan, Quark, Queterra, Santen, Santhera, Sensimed, grants and personal fees from Alcon, Pfizer, and grants from NIH AA programme outside the submitted work, and has a patent contact lens tonometer pending; PJF reports an unrestricted grant from Alcon (US) and grants and personal fees from Allergan (UK) and Zeus (EU); no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

**Ethical approval:** The work was approved by the East Norfolk and Waveney NHS research governance committee (2005EC07L) and the Norfolk research ethics committee (05/Q0101/191).

**Data sharing:** Requests for data sharing/access should be submitted to the EPIC Management Committee via Mrs Shabina Hayat (sah63@ic.ac.uk). Applications will be judged on a case by case basis, determined by the scientific merit, in line with MRC guidelines (https://www.mrc.ac.uk/publications/browse/mrc-policy-and-guidance-on-sharing-of-research-data-from-population-and-patient-studies/).

**Transparency:** The lead author (the manuscript’s guarantor) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

1 World Health Organization. Fact Sheet No. 282. Visual impairment and blindness June 2012. http://www.who.int/mediacentre/factsheets/fs282/en.
2 Bunce C, Xing W, Wormald R. Causes of blind and partial sight certifications in England and Wales: April 2007-March 2008. Eye (Lond) 2010;24:1693-9. doi:10.1038/eye.2010.122
3 Foster Pt, Buhmann R, Quigley HA, Johnson GJ. The definition and classification of glaucoma in prevalence surveys. Br J Ophthalmol 2002;86:238-42. doi:10.1136/bjo.86.2.338
4 Health and Social Care Information Centre. Hospital outpatient activity 2014-15: primary diagnosis December 2015. http://digital.nhs.uk/article/2021/Website/SeaechProductid/198794&outpatient+actiivity?rel=Item&size=10&page=1&area=both - top.
5 Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014;121:2081-90. doi:10.1016/j.ophtha.2014.05.013
6 de Voogd S, Iksan M, Wolfs RC, Jansonnis NM, Hofman A, de Jong PT. Incidence of open-angle glaucoma in a general elderly population: the Rotterdam Study. Ophthalmology 2005;112:1487-93. doi:10.1016/j.ophtha.2005.04.018
7 Nemesure B, Honkanen R, Henris A, Wu JX, Leske MC. Barbados Eye Studies Group. Incidence of open-angle glaucoma and intraocular pressure. Ophthalmology 2007;114:1810-5. doi:10.1016/j.ophtha.2007.04.003
8 Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z. EMGT Group. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007;114:1965-72. doi:10.1016/j.ophtha.2007.03.016
9 Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol 1991;109:1090-5. doi:10.1001/archopht.1991.010800050026
10 Dias NA, Frants YV, Smeulders MJ, et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 1999;80(Suppl 1):95-101.
11 Khawaja AP, Chan MP, Hayat S, et al. The EPIC Norfolk Eye Study rationale, methods and a cross-sectional analysis of visual impairment in a population-based cohort. BMJ Open 2013;3:e002684. doi:10.1136/bmjopen-2013-002684
12 Luce DA. Determining in vivo biomechanical properties of the cornea with an ocular response analyzer. (Corneal Refract Ther) 2005;31:156-62. doi:10.1016/j.jcrto.2004.10.044
13 Cook JA, Botello AP, Eiders A, et al. Surveillance of Ocular Hypertension Study Group. Systematic review of the agreement of tonometers with Goldmann applanation tonometry. Ophthalmology 2012;119:1552-7. doi:10.1016/j.ophtha.2012.02.030
14 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007;335:806-8. doi:10.1136/bmj.39355.541782.AD
15 ONS. Population estimates by single year of age and sex for local authorities in the UK, mid-2014. Office for National Statistics, 2015.
16 Tielsch JM, Katz J, Singh K, et al. A population-based evaluation of glaucoma screening: the Baltimore Eye Survey. Am J Epidemiol 1991;134:1102-13. doi:10.1093/oxfordjournals.aje.a116013
17 Varma R, Yng-Lai M, Francis BA, et al. Los Angeles Latino Eye Study Group. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. Ophthalmology 2004;111:1439-48. doi:10.1016/j.ophtha.2004.01.025
18 Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology 1996;103:1661-9. doi:10.1016/S0161-9418(95)70209-8
19 Weih LM, Nanjan M, McCarty CA, Taylor HR. Prevalence and predictors of open-angle glaucoma: results from the visual impairment project. Ophthalmology 2001;108:1966-72. doi:10.1016/S0161-6420(01)00799-0
20 Dielemans I, Vingerling JR, Wolfs RC, Hofman A, Grobbee DE, de Jong PT. The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands. The Rotterdam Study. Ophthalmology 1994;101:1051-5. doi:10.1016/S0161-6420(94)31090-6
21 Nizankowska MH, Kaczmarek R. Prevalence of glaucoma in the wrocław population. The wrocław epidemiological study. Ophthalmologica 2005;219:363-71. doi:10.1159/000085880
22 Topouzis F, Wilson MR, Harris A, et al. Prevalence of open-angle glaucoma in Greece: the Thessaloniki Eye Study. Am J Ophthalmol 2007;144:511-9. doi:10.1016/j.ajo.2006.09.029
23 Foster Pt, Qureshi FT, Machin D, et al. The prevalence of open-angle glaucoma in Chinese residents of Singapore: a cross-sectional population survey of the Tanjong Pagar district. Arch Ophthalmol 2000;118:1105-11. doi:10.1001/archopht.118.8.1105
24 He M, Foster PJ, Ge J, et al. Prevalence and clinical characteristics of glaucoma in adult Chinese: a population-based study in Liwan District, Guangzhou. Invest Ophthalmol Vis Sci 2006;47:2782-8. doi:10.1167/iovs.06-0051
25 Iwase A, Suzuki Y, Araie M, et al. Tajimi Study Group, Japan Glaucoma Society. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. *Ophthalmology* 2004;111:1641-8.

26 Shen SY, Wong TY, Foster PJ, et al. The prevalence and types of glaucoma in malay people: the Singapore Malay eye study. *Invest Ophthalmol Vis Sci* 2008;49:3846-51. doi:10.1167/iovs.08-1759

27 Coffey M, Reidy A, Wormald R, Xian WX, Wright L, Courtney P. Prevalence of glaucoma in the west of Ireland. *Br J Ophthalmol* 1999;77:17-21. doi:10.1136/bjo.77.1.17

28 Reidy A, Minassian DC, Vafidis G, et al. Prevalence of serious eye disease and visual impairment in a north London population: population based, cross sectional study. *BMJ* 1998;316:1643-6. doi:10.1136/bmj.316.7145.1643

29 Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. *Br J Ophthalmol* 2006;90:262-7. doi:10.1136/bjo.2005.081224

30 Burr JM, Mowatt G, Hernández R, et al. The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. *Health Technol Assess* 2007;11:i-iv, ix-x, 1-190. doi:10.3310/hta11410

31 Rudnicka AR, Mita-S, Owen CG, Cook DG, Ashby D. Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. *Invest Ophthalmol Vis Sci* 2006;47:4254-61. doi:10.1167/iovs.06-0299

32 Telisch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. *JAMA* 1991;266:369-74. doi:10.1001/jama.1991.03470030069026

33 National Collaborating Centre for Acute Care. Glaucoma: diagnosis and management of chronic open angle glaucoma and ocular hypertension. [CG85] National Institute for Health and Clinical Excellence, 2009.

34 Lockwood AJ, Kirwan JF, Ashleigh Z. Optometrists referrals for glaucoma assessment: a prospective survey of clinical data and outcomes. *Eye (Lond)* 2010;24:1515-9. doi:10.1038/eye.2010.77

35 Khan S, Clarke J, Kotecha A. Comparison of optometrist glaucoma referrals against published guidelines. *Ophthalmic Physiol Opt* 2012;32:472-7. doi:10.1111/j.1475-1313.2012.00943.x

36 Kapetanakis VV, Chan MP, Foster PJ, Cook DG, Owen CG, Rudnicka AR. Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): a systematic review and meta-analysis. *Br J Ophthalmol* 2016;100:86-93. doi:10.1136/bmjophthalmol-2015-307223

37 Leibowitz HM, Krugler DE, Maunder LR, et al. The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. *Surv Ophthalmol* 1980;24(Suppl):335-610.

38 Leske MC, Connell AM, Schachat AP, Hyman L. The Barbados Eye Study Prevalence of open angle glaucoma. *Arch Ophthalmol* 1994;112:821-9. doi:10.1001/archophthalmol.1994.01090180121046